Celyad Oncology SA (CYAD.BR)

EUR 0.48

(-0.83%)

Total Assets Summary of Celyad Oncology SA

Celyad Oncology SA's latest annual total assets in 2023 was 16.28 Million EUR , down -17.42% from previous year.
Celyad Oncology SA's latest quarterly total assets in 2024 Q2 was 12.84 Million EUR , down 0.0% from previous quarter.
Celyad Oncology SA reported annual total assets of 19.71 Million EUR in 2022, down -75.34% from previous year.
Celyad Oncology SA reported annual total assets of 79.94 Million EUR in 2021, up 20.97% from previous year.
Celyad Oncology SA reported quarterly total assets of 16.28 Million EUR for 2023 FY, down -17.42% from previous quarter.
Celyad Oncology SA reported quarterly total assets of 16.28 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Assets Chart of Celyad Oncology SA (2023 - 2011)

Historical Annual Total Assets of Celyad Oncology SA (2023 - 2011)

Year	Total Assets	Total Assets Growth
2023	16.28 Million EUR	-17.42%
2022	19.71 Million EUR	-75.34%
2021	79.94 Million EUR	20.97%
2020	66.08 Million EUR	-26.44%
2019	89.83 Million EUR	-4.73%
2018	94.29 Million EUR	21.48%
2017	77.62 Million EUR	-44.08%
2016	138.8 Million EUR	-12.99%
2015	159.52 Million EUR	262.75%
2014	43.97 Million EUR	35.79%
2013	32.38 Million EUR	135.6%
2012	13.74 Million EUR	99.87%
2011	6.87 Million EUR	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	12.84 Million EUR	0.0%
2023 FY	16.28 Million EUR	-17.42%
2023 Q4	16.28 Million EUR	0.0%
2023 Q2	12.17 Million EUR	0.0%
2022 Q1	69.21 Million EUR	-13.42%
2022 Q4	19.71 Million EUR	0.0%
2022 FY	19.71 Million EUR	-75.34%
2022 Q2	63.14 Million EUR	-8.78%
2021 Q4	79.94 Million EUR	37.37%
2021 Q2	62.68 Million EUR	0.95%
2021 Q1	62.1 Million EUR	-6.03%
2021 FY	79.94 Million EUR	20.97%
2021 Q3	58.19 Million EUR	-7.16%
2020 Q4	66.08 Million EUR	0.0%
2020 Q2	75.76 Million EUR	0.0%
2020 FY	66.08 Million EUR	-26.44%
2019 Q4	89.83 Million EUR	0.0%
2019 Q2	81.35 Million EUR	0.0%
2019 FY	89.83 Million EUR	-4.73%
2018 Q4	94.29 Million EUR	0.0%
2018 FY	94.29 Million EUR	21.48%
2018 Q2	109.05 Million EUR	0.0%
2017 FY	77.62 Million EUR	-44.08%
2017 Q2	120.29 Million EUR	0.0%
2017 Q4	77.62 Million EUR	0.0%
2016 FY	138.8 Million EUR	-12.99%
2016 Q4	138.8 Million EUR	0.0%
2016 Q2	139.99 Million EUR	0.0%
2015 FY	159.52 Million EUR	262.75%
2015 Q2	183.29 Million EUR	0.0%
2015 Q4	159.52 Million EUR	0.0%
2014 FY	43.97 Million EUR	35.79%
2014 Q2	51.8 Million EUR	0.0%
2014 Q4	43.97 Million EUR	0.0%
2013 Q4	32.38 Million EUR	0.0%
2013 Q2	15.04 Million EUR	0.0%
2013 FY	32.38 Million EUR	135.6%
2012 Q4	13.74 Million EUR	0.0%
2012 FY	13.74 Million EUR	99.87%
2011 FY	6.87 Million EUR	0.0%

Peer Total Assets Comparison of Celyad Oncology SA

Name	Total Assets	Total Assets Difference
Nicox S.A.	52.98 Million EUR	69.268%
European Medical Solutions	43.75 Million EUR	62.791%
FERMENTALG	50.24 Million EUR	67.594%
argenx SE	4.11 Billion EUR	99.604%
BioSenic S.A.	9.55 Million EUR	-70.332%
Hyloris Pharmaceuticals SA	47.68 Million EUR	65.852%
Onward Medical N.V.	43.62 Million EUR	62.681%
Oxurion NV	6.55 Million EUR	-148.58%
PHAXIAM Therapeutics S.A.	51.3 Million EUR	68.266%
Financière de Tubize SA	1.92 Billion EUR	99.152%
UCB SA	15.53 Billion EUR	99.895%